What Happens Between the Laboratory and the Patient? Translational Medicine Explained

A new drug, diagnostic test, or treatment method rarely reaches the patient immediately after being discovered in the laboratory. Between the idea and its real-world application in healthcare lies a long, complex, and costly process. Translational medicine addresses precisely this stage - a field that is becoming increasingly important in Latvia as well.

From Discovery to Treatment - Where Do Ideas Get Lost?

In biomedical research, the term “valley of death” often comes up - the stage where promising scientific ideas stall because of insufficient funding, regulatory experience, clinical validation, or industry collaboration. Researchers excel in their scientific fields, but the path to the patient requires additional competencies - understanding clinical trials, safety requirements, data quality, and health technology assessment.

This gap between fundamental science and practical application is a key reason why translational medicine is developing across Europe and globally.

What Is Translational Medicine?

Translational medicine is an interdisciplinary approach that helps turn scientific discoveries into real medical solutions - including drugs, vaccines, diagnostic tools, or digital health technologies. It is often described as “from bench to bedside.”

Unlike traditional academic research, translational medicine asks practical questions from an early stage: Can this idea be safely tested in humans? What data will regulatory authorities and policymakers require? Does the solution have the potential to enter the healthcare system?

European-Level Support: EATRIS

To help researchers navigate this complex stage, Europe established EATRIS ERIC - the European Infrastructure for Translational Medicine. It brings together leading research centers and hospitals across several European countries, offering practical support for the development of translational research.

EATRIS provides access to expertise and platforms that help assess a project’s translational potential, prepare for clinical studies, navigate regulatory requirements, and ensure high-quality data. This support reduces risk and accelerates the journey from the laboratory to the patient.

Why Is This Important for Latvia?

Latvia is a country with strong academic potential but a limited domestic market and resources. Participation in European research infrastructures is therefore strategically important. EATRIS gives Latvian researchers the opportunity to be part of a wide European collaboration network and develop projects that would otherwise be difficult to realize solely at the national level.

Latvia’s participation in EATRIS is coordinated by Rīgas Stradiņa universitāte, in collaboration with hospitals and research institutes. This enables the creation of a unified translational medicine ecosystem where science, clinical practice, and innovation work together.

From Idea to Patient - A Collaborative Effort

Translational medicine is not the task of a single project or institution. It requires close collaboration among researchers, clinicians, policymakers, industry, and patients. EATRIS helps make this collaboration systematic and accessible, even for smaller countries.

For Latvia, this means the opportunity not only to participate in international projects but also to develop its own solutions that can improve patient care both nationally and beyond.

Looking Ahead

In the coming years, the importance of translational medicine will only grow. Personalized medicine, new therapies, and research-based solutions require an increasingly tight connection between science, clinical practice, patients, policymakers, and society. EATRIS and similar infrastructures serve as bridges that make this connection possible.

Latvia’s involvement in this process is an opportunity to strengthen not only science but also the healthcare system and the overall innovation environment.

Information provided within the project “RSU participation in the Horizon Europe programme” (No. 1.1.1.5/3/25/I/014).

*project no. 1.1.1.5/3/25/I/014